Login / Signup

Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study.

Yiran XieHaoxiang ZhuYifei GuoZhenxuan MaXun QiFeifei YangRi-Cheng MaoJi-Ming Zhang
Published in: Canadian journal of gastroenterology & hepatology (2022)
plus NTs may lead to more HBsAg reduction, especially in HBeAg-positive and "add-on" patients.
Keyphrases
  • hepatitis b virus
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • stem cells
  • mesenchymal stem cells
  • cell therapy
  • liver fibrosis